NCT03611114

Brief Summary

Epidemiological studies have indicated that the consumption of citrus fruit is inversely associated with the risk of cardiovascular disease. However, clinical data regarding the effects of blood orange juice upon endothelial function is scarce. This randomised, crossover study investigates whether blood orange juice compared to a control drink improves blood vessel function and other cardiovascular health indicators (such as blood pressure and blood lipids). All the subjects will be asked to consume blood orange juice and a control drink in a randomised order, each over a 2-week period, divided by a 1-week wash out period.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for not_applicable healthy

Timeline
Completed

Started Jan 2017

Typical duration for not_applicable healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 10, 2017

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 21, 2017

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

April 18, 2018

Completed
4 months until next milestone

First Posted

Study publicly available on registry

August 2, 2018

Completed
28 days until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2018

Completed
Last Updated

July 19, 2019

Status Verified

July 1, 2019

Enrollment Period

5 months

First QC Date

April 18, 2018

Last Update Submit

July 18, 2019

Conditions

Keywords

endothelial functionflow mediated dilationlipid profileblood pressureflavanonesCaucasian

Outcome Measures

Primary Outcomes (1)

  • Changes in flow mediated dilation between baseline and endpoint within the intervention group vs. control group

    FMD will be evaluated prior to and following 2-week consumption of either blood orange juice or a control drink.

    Baseline and 2 weeks; after 1-week wash out, another baseline and 2 weeks.

Secondary Outcomes (7)

  • Changes in blood pressure between baseline and endpoint within the intervention group vs. control group

    Baseline and 2 weeks; after 1-week wash out, another baseline and 2 weeks.

  • Changes in lipid profile between baseline and endpoint within the intervention group vs. control group

    Baseline and 2 weeks; after 1-week wash out, another baseline and 2 weeks.

  • Changes in high sensitivity C-reactive protein between baseline and endpoint within the intervention group vs. control group

    Baseline and 2 weeks; after 1-week wash out, another baseline and 2 weeks.

  • Changes in endothelin-1 (ET-1) between baseline and endpoint within the intervention group vs. control group

    Baseline and 2 weeks; after 1-week wash out, another baseline and 2 weeks.

  • Changes in oestradiol between baseline and endpoint within the intervention group vs. control group

    Baseline and 2 weeks; after 1-week wash out, another baseline and 2 weeks.

  • +2 more secondary outcomes

Study Arms (2)

Blood orange juice

EXPERIMENTAL

Subjects will be asked to consume blood orange juice (400 ml/day) for 2 weeks.

Dietary Supplement: Blood orange juice

Control drink

PLACEBO COMPARATOR

Subjects will be asked to consume a control drink (400 ml/day) for 2 weeks.

Dietary Supplement: Control drink

Interventions

Blood orange juiceDIETARY_SUPPLEMENT
Blood orange juice
Control drinkDIETARY_SUPPLEMENT
Control drink

Eligibility Criteria

Age20 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Generally healthy
  • Caucasians (of European origin)
  • BMI \> 25 kg/m2

You may not qualify if:

  • Presence of cardiovascular diseases
  • Smoking
  • Use of medications or dietary supplements (vitamins, antioxidants)
  • On a special diet and/or a training program to change weight

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Leeds

Leeds, LS2 9JT, United Kingdom

Location

Related Publications (4)

  • Muller-Delp JM, Lubahn DB, Nichol KE, Philips BJ, Price EM, Curran EM, Laughlin MH. Regulation of nitric oxide-dependent vasodilation in coronary arteries of estrogen receptor-alpha-deficient mice. Am J Physiol Heart Circ Physiol. 2003 Nov;285(5):H2150-7. doi: 10.1152/ajpheart.00966.2002. Epub 2003 Jul 24.

    PMID: 12881205BACKGROUND
  • Perticone F, Ceravolo R, Candigliota M, Ventura G, Iacopino S, Sinopoli F, Mattioli PL. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes. 2001 Jan;50(1):159-65. doi: 10.2337/diabetes.50.1.159.

    PMID: 11147782BACKGROUND
  • Thijssen DH, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, Parker B, Widlansky ME, Tschakovsky ME, Green DJ. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol. 2011 Jan;300(1):H2-12. doi: 10.1152/ajpheart.00471.2010. Epub 2010 Oct 15.

    PMID: 20952670BACKGROUND
  • Li L, Lyall GK, Martinez-Blazquez JA, Vallejo F, A Tomas-Barberan F, Birch KM, Boesch C. Blood Orange Juice Consumption Increases Flow-Mediated Dilation in Adults with Overweight and Obesity: A Randomized Controlled Trial. J Nutr. 2020 Sep 1;150(9):2287-2294. doi: 10.1093/jn/nxaa158.

MeSH Terms

Conditions

OverweightObesity

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Lu Li, PhD

    University of Leeds

    PRINCIPAL INVESTIGATOR
  • Karen M Birch, PhD

    University of Leeds

    STUDY DIRECTOR
  • Christine Bosch, PhD

    University of Leeds

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD

Study Record Dates

First Submitted

April 18, 2018

First Posted

August 2, 2018

Study Start

January 10, 2017

Primary Completion

June 21, 2017

Study Completion

August 30, 2018

Last Updated

July 19, 2019

Record last verified: 2019-07

Data Sharing

IPD Sharing
Will not share

Locations